A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the APPENDIX.
A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed)
Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.
Distention of KIDNEY with the presence of PUS and suppurative destruction of the renal parenchyma. It is often associated with renal obstruction and can lead to total or nearly total loss of renal function.
A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1702)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
A benign neoplasm of the ovary.
Tumors or cancer of the PAROTID GLAND.
A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
Tumors or cancer of the BILE DUCTS.
Retroperitoneal neoplasms are a diverse group of tumors that originate in the retroperitoneal space, which is the area behind the peritoneum and includes the kidneys, adrenal glands, pancreas, and major blood vessels.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumors or cancer of the SALIVARY GLANDS.
Surgical removal of the pancreas. (Dorland, 28th ed)
Organic compounds containing both the hydroxyl and carboxyl radicals.
The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)

Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms. (1/75)

Between 1976 and 1996, 176 borderline ovarian tumours were registered in the Cancer Registry of the Swiss canton of Vaud, corresponding to an age-adjusted incidence (world standard) of 2.7 in 100,000. Incidence rose from 1.7 per 100,000 during 1976-81 to 2.7 per 100,000 during 1987-91, and then levelled off; 58% of cases were serous and 41% mucinous. Relative survival was 94% at 10 years; 18 second neoplasms were observed, compared with 10.3 expected, and there was a significant excess of invasive ovarian cancers (four observed, including three synchronous, compared with 0.4 expected).  (+info)

Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? (2/75)

OBJECTIVE: To determine whether the long-term behavior of cystic mucinous neoplasms of the pancreas could be predicted using a novel, precisely defined classification of benign mucinous cystadenomas, noninvasive proliferative cystic mucinous neoplasms, and invasive mucinous cystadenocarcinomas. The primary interest was to obtain long-term follow-up after complete resection to determine the recurrence rates based on this objective classification. BACKGROUND: Current understanding is that all cystic mucinous neoplasms of the pancreas are potentially malignant and that mucinous cystadenomas, when completely removed, are biologically benign. Cystadenocarcinomas are thought to be less aggressively malignant than ordinary ductal adenocarcinoma, but reported recurrence rates vary widely and are unpredictable. METHODS: All patients who underwent "curative" resection for cystic mucinous neoplasms at Mayo Clinic Rochester from 1940 to 1997 were identified. All available pathology slides, gross specimens, and clinical records were reviewed, eliminating patients with inadequate documentation. Neoplasms were reclassified as mucinous cystadenomas, noninvasive proliferative mucinous cystic neoplasms, or invasive cystadenocarcinomas based on specific histologic criteria. RESULTS: Of 84 patients (70 women, 14 men) with cystic mucinous neoplasms of the pancreas, 54 were classified as cystadenomas, 23 as noninvasive proliferative cystic mucinous neoplasms, and only 7 as cystadenocarcinomas. Recurrent disease developed in none of the 77 patients without invasion, but 5 of the 6 patients surviving resection for cystadenocarcinomas died of recurrent cystadenocarcinoma within 5 years. CONCLUSIONS: When the neoplasm is completely resected and subjected to adequate histopathologic examination based on these objective criteria, absence of tissue invasion predicts a curative operation and detailed follow-up may be unnecessary. In contrast, a histologic diagnosis of invasive cystadenocarcinoma portends a dismal prognosis, similar to that of typical ductal adenocarcinoma of the pancreas.  (+info)

Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. (3/75)

Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis. To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25. LOH was observed for at least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25. Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801. One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors.  (+info)

Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. (4/75)

In the present study we examined the localization and overexpression of heat shock proteins (hsps), mainly hsp90, in pancreatic carcinoma tissue compared with control tissue (including chronic pancreatitis and normal pancreas tissue), with the aid of immunohistochemical staining, in situ hybridization and reverse transcriptase polymerase chain reaction. Hsp90 alpha mRNA was overexpressed more highly in pancreatic carcinoma than in the control tissue. The proliferating-cell-nuclear-antigen labeling index was also high in pancreatic carcinoma tissue compared with the other tissue. These findings suggest that the overexpression of hsp90 alpha mRNA in carcinomas may be correlated with cell proliferation. However, hsp90 beta was constitutively overexpressed almost equally in all groups of pancreatic tissue including pancreatic carcinoma, chronic pancreatitis and normal pancreas tissue. Immunohistochemical staining demonstrated a differentiation in the expression of hsp90 between histological types of pancreatic carcinoma. These findings suggest that hsp90 alpha is involved in carcinogenesis and that hsp90 beta is correlated to structural conformation. Hsp90 alpha and hsp90 beta seem to perform different functions in tissue containing malignant cells. P53, MDM2 and WAF1, that were cell-cycle-related oncogene product were more strongly expressed in the nuclei of the cancer cells of the cancer tissue. Especially, MDM2 was more strongly expressed in mucinous carcinoma and the mucin secreting tissues surrounding pancreatic carcinoma tissue. The expression of MDM2 protein might also be correlated to secretion systems during structural conformation and be correlated to hsp90 beta.  (+info)

P73 gene expression in ovarian cancer tissues and cell lines. (5/75)

Thep73 gene, a homology of p53, is a new candidate of imprinting and tumor suppressor gene. To investigate the role of p73 in ovarian cancer, we studied the allelic expression in 56 cases of ovarian cancer using StyI polymorphism analysis. We also examined p73 expression by semi-quantitative reverse transcription-PCR as well as by Western blot analysis and DNA methylation study of the CpG island in exon 1 in ovarian cancer tissues and cell lines. Loss of heterozygosity was found in 8.3% (2 of 24) of the cases. Biallelic expression was demonstrated in 91.7% (22 of 24) of the tumor samples, in 70.8% (17 of 24) of the normal samples, and in 1 ovarian cancer cell line. Imbalanced expression and monoallelic expression were found in three and two pairs of matched samples, respectively. Overexpression of p73 was found in advanced ovarian cancer rather than in early-stage disease or in borderline ovarian tumor. No significant difference was found in the p53 expression. Three cell lines with absent p73 protein expression and one tumor sample with monoallelic expression were methylated in the CpG island. Demethylation in SKOV3 cell line using 5-azacytidine can reactivate the expression of this gene in both the mRNA and the protein level. Our results indicated that p73 was not imprinted in most of the ovarian cancer and normal tissues, but it could be involved in the advanced ovarian cancer through overexpression. DNA methylation may contribute to the lack of p73 expression.  (+info)

The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. (6/75)

Proteolysis mediated by matrix metalloproteinases (MMPs) and serine proteinases is associated with cancer invasion and metastasis. Activation of latent proMMPs, and especially the proforms of the type IV collagen degrading gelatinases A and B (proMMP-2 and proMMP-9), is thought to be a critical step in this process. We have recently found that human tumour-associated trypsin-2 is a potent activator of proMMP-9 and it also activates proMMP-2 in vitro. Trypsinogen, MMP-2, and MMP-9 are expressed in ovarian cancer. To elucidate the function of trypsin in vivo, we studied whether high concentrations of trypsinogen-1, trypsinogen-2, their alpha(1)-proteinase inhibitor (API) complexes, and tumour-associated trypsin inhibitor (TATI) are associated with proMMP-2 and proMMP-9 activation in ovarian tumour cyst fluids. Zymography and immunofluorometric analysis of 61 cyst fluids showed a significant association between high trypsin concentrations and the activation of MMP-9 (P = 0.003-0.05). In contrast, the trypsin concentrations were inversely associated with the activation of MMP-2 (P = 0.01-0.02). Immunohistochemical analysis of ovarian tumour tissue demonstrated expression of trypsinogen-2 and TATI in the secretory epithelium. MMP-2 was detected both in stromal and epithelial cells whereas MMP-9 was detected in neutrophils and macrophage-like cells in stromal and epithelial areas. These results suggest that trypsin may play a role in the regulation of the MMP-dependent proteolysis associated with invasion and metastasis of ovarian cancer.  (+info)

Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. (7/75)

This study investigates whether and to what extent cyclooxygenase type-2 (COX-2) and inducible nitric oxide-synthase (iNOS), both known to have an immunosuppressive effect, are expressed in human ovarian tumors. Because COX-2 and iNOS can be expressed by activated macrophages, the presence of tumor-associated macrophages and the expression of COX-2 and iNOS by these tumor-associated macrophages were determined. The results obtained may provide insight into the function of COX-2 and iNOS expression by tumors. The expression of COX-2 and iNOS in tumor cells and macrophages was assessed in 18 malignant, 15 borderline, and 14 benign human ovarian tumors by immunohistochemical staining of frozen tissue sections. The intra- and peritumoral macrophages were stained using an anti-CD68 monoclonal antibody. Most of the malignant tumors (15 of 18), 10 of 15 borderline, and 9 of 14 benign tumors showed COX-2 expression in the epithelial cells, a result which indicates that COX-2 expression is not exclusive to malignancy. In addition, COX-2 staining was more intense in the epithelial cells of benign and borderline tumors than in malignant tumors. Weak iNOS staining was observed in 5 of 18 malignant, 4 of 15 borderline, and 5 of 14 benign tumors. The number of tumor-associated macrophages varied widely between the different tumors. The highest number of tumor-associated macrophages (> or =20/0.125 mm(2)) was observed in malignant tumors, whereas low to moderate intra- and peritumoral macrophage infiltration (5-20/0.125 mm(2)) was observed in the borderline and benign tumors. COX-2-positive tumor-associated macrophages were found in 3 of 18 malignant tumors, 7 of 15 borderline tumors, and 1 of 14 benign tumors. The number of COX-2-positive tumor-associated macrophages ranged from 3 to 30% of the total macrophage population. Some malignant (4 of 18), borderline (5 of 15), and benign (2 of 14) tumors contained iNOS-positive macrophages. Notable was that COX-2- and iNOS-positive macrophages were predominantly located in the tumor stroma, the regions between tumor and stroma, and in the lumina of the tumor when located in the tumor tissue. These data indicate that not only malignant but also borderline and benign ovarian tumors can exhibit increased levels of COX-2 and iNOS expression. In addition, a small proportion of the tumor-associated macrophages found in malignant, borderline, and benign tumors seems to be in an activated state, judged by their iNOS and COX-2 expression. This subpopulation of tumor-associated macrophages was invariably located in the tumor stroma or in the lumina of the tumor, specifically suggesting that macrophages outside the tumor can be tumor cytotoxic.  (+info)

Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. (8/75)

Recently, some studies have shown that delayed scanning with (18)F-FDG PET may help to differentiate malignant from benign pancreatic lesions. However, no study has evaluated the relationship between temporal changes in (18)F-FDG uptake and expression of hexokinase or glucose transporter. METHODS: Twenty-one consecutive patients with pancreatic cancer were studied preoperatively by dual-phase (18)F-FDG PET, performed 1 and 2 h after injection of (18)F-FDG. The standardized uptake value (SUV) of the pancreatic cancer was determined, and the retention index (RI) (%) was calculated by subtracting the SUV at 1 h (SUV1) from the SUV at 2 h (SUV2) and dividing by SUV1. The percentages of cells strongly expressing hexokinase type-II (HK-II) and glucose transporter-1 (GLUT-1) were scored on a 5-point scale (1 = 0%-20%, 2 = 20%-40%, 3 = 40%-60%, 4 = 60%-80%, 5 = 80%-100%) by visual analysis of immunohistochemical staining of paraffin sections from the tumor specimens using anti-HK-II and anti-GLUT-1 antibody (HK-index and G-index, respectively). RESULTS: SUV2 (mean +/- SD, 5.7 +/- 2.6) was higher than SUV1 (5.1 +/- 2.1), with an RI of 8.5 +/- 11.0. Four cases of cancer, in which SUV2 showed a decline from SUV1, showed a low HK-index (1.8 +/- 1.1), whereas 4 cases with an RI of > or =20 and 13 cases with an intermediate RI (0-20) showed significantly higher HK-indices (4.3 +/- 0.7 and 3.1 +/- 1.5, respectively; P < 0.05). RI showed a positive correlation with HK-index, with an R(2) of 0.27 (P < 0.05), but no significant correlation with the G-index. SUV1 showed no relationship with the HK-index but showed a weak positive correlation with the G-index, with an R(2) of 0.05 (P = 0.055). CONCLUSION: These preliminary findings suggest that the RI obtained from dual-phase (18)F-FDG PET can predict HK-II expression and that the SUV (at 1 h) has a positive correlation with GLUT-1 expression but not with HK-II expression.  (+info)

Cystadenocarcinoma is a type of tumor that arises from the epithelial lining of a cyst, and it has the potential to invade surrounding tissues and spread (metastasize) to other parts of the body. It typically affects glandular organs such as the ovaries, pancreas, and salivary glands.

Cystadenocarcinomas can be classified into two types: serous and mucinous. Serous cystadenocarcinomas produce a watery fluid, while mucinous cystadenocarcinomas produce a thick, mucus-like fluid. Both types of tumors can be benign or malignant, but malignant cystadenocarcinomas are more aggressive and have a higher risk of metastasis.

Symptoms of cystadenocarcinoma depend on the location and size of the tumor. In some cases, there may be no symptoms until the tumor has grown large enough to cause pain or other problems. Treatment typically involves surgical removal of the tumor, along with any affected surrounding tissue. Chemotherapy and radiation therapy may also be used in some cases to help prevent recurrence or spread of the cancer.

Mucinous cystadenocarcinoma is a type of cancer that arises from the mucin-producing cells in the lining of a cyst. It is a subtype of cystadenocarcinoma, which is a malignant tumor that develops within a cyst. Mucinous cystadenocarcinomas are typically found in the ovary or pancreas but can also occur in other organs such as the appendix and the respiratory tract.

These tumors are characterized by the production of large amounts of mucin, a gel-like substance that can accumulate within the cyst and cause it to grow. Mucinous cystadenocarcinomas tend to grow slowly but can become quite large and may eventually spread (metastasize) to other parts of the body if left untreated.

Symptoms of mucinous cystadenocarcinoma depend on the location and size of the tumor, but they may include abdominal pain or discomfort, bloating, changes in bowel movements, or vaginal bleeding. Treatment typically involves surgical removal of the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The prognosis for mucinous cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis and the patient's overall health.

Cystadenoma is a type of benign tumor (not cancerous), which arises from glandular epithelial cells and is covered by a thin layer of connective tissue. These tumors can develop in various locations within the body, including the ovaries, pancreas, and other organs that contain glands.

There are two main types of cystadenomas: serous and mucinous. Serous cystadenomas are filled with a clear or watery fluid, while mucinous cystadenomas contain a thick, gelatinous material. Although they are generally not harmful, these tumors can grow quite large and cause discomfort or other symptoms due to their size or location. In some cases, cystadenomas may undergo malignant transformation and develop into cancerous tumors, known as cystadenocarcinomas. Regular medical follow-up and monitoring are essential for individuals diagnosed with cystadenomas to ensure early detection and treatment of any potential complications.

Papillary cystadenocarcinoma is a type of cancer that arises from the epithelial cells lining a cyst. It is called "papillary" because the tumor has finger-like projections called papillae, which are made up of fibrovascular cores covered by neoplastic cells.

Cystadenocarcinoma is a malignant tumor that has the potential to invade surrounding tissues and spread (metastasize) to other parts of the body. Papillary cystadenocarcinomas can occur in various organs, including the ovaries, pancreas, and lungs.

The symptoms of papillary cystadenocarcinoma depend on the location of the tumor. For example, an ovarian papillary cystadenocarcinoma may cause abdominal pain or bloating, while a lung papillary cystadenocarcinoma may cause coughing or shortness of breath.

The diagnosis of papillary cystadenocarcinoma typically involves imaging tests such as ultrasound, CT scan, or MRI, followed by a biopsy to confirm the presence of cancer cells. Treatment options include surgery to remove the tumor, chemotherapy, and radiation therapy. The prognosis for papillary cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis, the location of the tumor, and the patient's overall health.

Cystadenocarcinoma, serous is a type of cystic tumor that arises from the lining of the abdominal or pelvic cavity (the peritoneum). It is called "serous" because the tumor cells produce a thin, watery fluid similar to serum.

Cystadenocarcinoma is a malignant (cancerous) tumor that can invade surrounding tissues and spread (metastasize) to other parts of the body. It typically affects women over the age of 50 and can cause symptoms such as abdominal pain, bloating, and changes in bowel or bladder habits.

Serous cystadenocarcinoma is a subtype of ovarian cancer that arises from the surface of the ovary. It can also occur in other organs, including the fallopian tubes, peritoneum, and endometrium. This type of tumor tends to grow slowly but can spread widely throughout the abdominal cavity, making it difficult to treat.

Treatment for serous cystadenocarcinoma typically involves surgery to remove the tumor and any affected tissues, followed by chemotherapy to kill any remaining cancer cells. The prognosis for this type of cancer depends on several factors, including the stage of the disease at diagnosis, the patient's age and overall health, and the response to treatment.

Mucinous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the mucous membranes of the body. It is most commonly found in the ovary, but can also occur in other locations such as the pancreas or appendix.

Mucinous cystadenomas are characterized by the production of large amounts of mucin, a slippery, gel-like substance that accumulates inside the tumor and causes it to grow into a cystic mass. These tumors can vary in size, ranging from a few centimeters to over 20 centimeters in diameter.

While mucinous cystadenomas are generally benign, they have the potential to become cancerous (mucinous cystadenocarcinoma) if left untreated. Symptoms of mucinous cystadenoma may include abdominal pain or swelling, bloating, and changes in bowel movements or urinary habits. Treatment typically involves surgical removal of the tumor.

Appendiceal neoplasms refer to various types of tumors that can develop in the appendix, a small tube-like structure attached to the large intestine. These neoplasms can be benign or malignant and can include:

1. Adenomas: These are benign tumors that arise from the glandular cells lining the appendix. They are usually slow-growing and may not cause any symptoms.
2. Carcinoids: These are neuroendocrine tumors that arise from the hormone-producing cells in the appendix. They are typically small and slow-growing, but some can be aggressive and spread to other parts of the body.
3. Mucinous neoplasms: These are tumors that produce mucin, a slippery substance that can cause the appendix to become distended and filled with mucus. They can be low-grade (less aggressive) or high-grade (more aggressive) and may spread to other parts of the abdomen.
4. Adenocarcinomas: These are malignant tumors that arise from the glandular cells lining the appendix. They are relatively rare but can be aggressive and spread to other parts of the body.
5. Pseudomyxoma peritonei: This is a condition in which mucin produced by an appendiceal neoplasm leaks into the abdominal cavity, causing a jelly-like accumulation of fluid and tissue. It can be caused by both benign and malignant tumors.

Treatment for appendiceal neoplasms depends on the type and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, or radiation therapy.

A mucocele is a mucus-containing cystic lesion that results from the accumulation of mucin within a damaged minor salivary gland duct or mucous gland. It is typically caused by trauma, injury, or blockage of the duct. Mucocele appears as a round, dome-shaped, fluid-filled swelling, which may be bluish or clear in color. They are most commonly found on the lower lip but can also occur on other areas of the oral cavity. Mucocele is generally painless unless it becomes secondarily infected; however, it can cause discomfort during speaking, chewing, or swallowing, and may affect aesthetics. Treatment usually involves surgical excision of the mucocele to prevent recurrence.

A cyst is a closed sac, having a distinct membrane and division between the sac and its surrounding tissue, that contains fluid, air, or semisolid material. Cysts can occur in various parts of the body, including the skin, internal organs, and bones. They can be caused by various factors, such as infection, genetic predisposition, or blockage of a duct or gland. Some cysts may cause symptoms, such as pain or discomfort, while others may not cause any symptoms at all. Treatment for cysts depends on the type and location of the cyst, as well as whether it is causing any problems. Some cysts may go away on their own, while others may need to be drained or removed through a surgical procedure.

Pyonephrosis is a medical condition characterized by the presence of pus in the renal pelvis, which is the part of the kidney where urine collects before flowing into the ureter. This occurs as a result of a severe infection that has spread to the kidney and caused pus to accumulate within the renal pelvis. Pyonephrosis can lead to serious complications such as sepsis, kidney damage, or even kidney failure if left untreated. It is typically treated with antibiotics and may require surgical intervention to drain the pus and remove any infected tissue.

A "mixed tumor, mesodermal" is not a widely recognized or currently used medical term in pathology. However, based on the context, it may refer to a type of tumor that contains a mixture of different cell types derived from the mesoderm, one of the three primary germ layers during embryonic development.

In general, a mixed tumor is a tumor composed of more than one type of tissue or cell type. In the context of soft tissue tumors, a "mixed tumor" may refer to a tumor with elements of both epithelial and mesenchymal differentiation, such as a pleomorphic adenoma.

However, in the context of mesodermal tissues, mixed tumors are not typically used to describe soft tissue tumors. Instead, the term "mixed" is more commonly used in the classification of certain types of ovarian tumors that contain both epithelial and mesenchymal elements, such as a Brenner tumor or a mullerian mixed tumor.

Therefore, it's important to provide more context or specify the body site when using the term "mixed tumor, mesodermal" to ensure accurate communication and understanding.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Biliary tract neoplasms refer to abnormal growths or tumors that develop in the biliary system, which includes the gallbladder, bile ducts inside and outside the liver, and the ducts that connect the liver to the small intestine. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Malignant biliary tract neoplasms are often referred to as cholangiocarcinoma if they originate in the bile ducts, or gallbladder cancer if they arise in the gallbladder. These cancers are relatively rare but can be aggressive and difficult to treat. They can cause symptoms such as jaundice (yellowing of the skin and eyes), abdominal pain, weight loss, and dark urine.

Risk factors for biliary tract neoplasms include chronic inflammation of the biliary system, primary sclerosing cholangitis, liver cirrhosis, hepatitis B or C infection, parasitic infections, and certain genetic conditions. Early detection and treatment can improve outcomes for patients with these neoplasms.

Papillary cystadenoma is a type of benign (non-cancerous) tumor that arises from the glandular cells in various organs. It is characterized by the growth of finger-like projections (papillae) inside the cysts. These tumors can occur in different parts of the body, including the ovaries, pancreas, and the lining of the abdominal cavity (peritoneum).

In general, papillary cystadenomas are slow-growing and do not typically spread to other organs. However, they can cause symptoms such as pain or discomfort if they become large enough to press on surrounding tissues. Treatment usually involves surgical removal of the tumor. It is important to note that while papillary cystadenomas are generally benign, there is a small risk that they may undergo malignant transformation and develop into cancerous tumors over time. Regular follow-up with a healthcare provider is recommended to monitor for any changes in the tumor or the development of new symptoms.

Parotid neoplasms refer to abnormal growths or tumors in the parotid gland, which is the largest of the salivary glands and is located in front of the ear and extends down the neck. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign parotid neoplasms are typically slow-growing, painless masses that may cause facial asymmetry or difficulty in chewing or swallowing if they become large enough to compress surrounding structures. The most common type of benign parotid tumor is a pleomorphic adenoma.

Malignant parotid neoplasms, on the other hand, are more aggressive and can invade nearby tissues and spread to other parts of the body. They may present as rapidly growing masses that are firm or fixed to surrounding structures. Common types of malignant parotid tumors include mucoepidermoid carcinoma, adenoid cystic carcinoma, and squamous cell carcinoma.

The diagnosis of parotid neoplasms typically involves a thorough clinical evaluation, imaging studies such as CT or MRI scans, and fine-needle aspiration biopsy (FNAB) to determine the nature of the tumor. Treatment options depend on the type, size, and location of the neoplasm but may include surgical excision, radiation therapy, and chemotherapy.

Barium sulfate is a medication that is commonly used as a contrast material in medical imaging procedures, such as X-rays and CT scans. It works by coating the inside of the digestive tract, making it visible on an X-ray or CT scan and allowing doctors to see detailed images of the stomach, intestines, and other parts of the digestive system.

Barium sulfate is a white, chalky powder that is mixed with water to create a thick, milky liquid. It is generally safe and does not cause significant side effects when used in medical imaging procedures. However, it should not be taken by individuals who have a known allergy to barium or who have certain digestive conditions, such as obstructions or perforations of the bowel.

It's important to note that while barium sulfate is an important tool for medical diagnosis, it is not a treatment for any medical condition and should only be used under the direction of a healthcare professional.

Pseudomyxoma Peritonei (PMP) is a rare, slow-growing, and invasive cancer that typically starts in the appendix as a low-grade mucinous neoplasm, although it can also arise from other organs of the abdominal cavity. The primary characteristic of PMP is the accumulation of copious amounts of gelatinous ascites (peritoneal fluid containing mucin) within the peritoneal cavity, causing progressive abdominal distension and discomfort.

The condition is classified into three main histological subtypes: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and hybrid tumors. DPAM is the least aggressive form, while PMCA is more invasive and has a worse prognosis.

The primary treatment for Pseudomyxoma Peritonei involves cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). This approach aims to remove all visible tumors and destroy any remaining cancer cells within the abdominal cavity. Early diagnosis and aggressive treatment can significantly improve the prognosis for patients with PMP, although long-term survival rates remain variable due to the disease's rarity and heterogeneity.

Intrahepatic bile ducts are the small tubular structures inside the liver that collect bile from the liver cells (hepatocytes). Bile is a digestive fluid produced by the liver that helps in the absorption of fats and fat-soluble vitamins from food. The intrahepatic bile ducts merge to form larger ducts, which eventually exit the liver and join with the cystic duct from the gallbladder to form the common bile duct. The common bile duct then empties into the duodenum, the first part of the small intestine, where bile aids in digestion. Intrahepatic bile ducts can become obstructed or damaged due to various conditions such as gallstones, tumors, or inflammation, leading to complications like jaundice, liver damage, and infection.

Bile duct neoplasms, also known as cholangiocarcinomas, refer to a group of malignancies that arise from the bile ducts. These are the tubes that carry bile from the liver to the gallbladder and small intestine. Bile duct neoplasms can be further classified based on their location as intrahepatic (within the liver), perihilar (at the junction of the left and right hepatic ducts), or distal (in the common bile duct).

These tumors are relatively rare, but their incidence has been increasing in recent years. They can cause a variety of symptoms, including jaundice, abdominal pain, weight loss, and fever. The diagnosis of bile duct neoplasms typically involves imaging studies such as CT or MRI scans, as well as blood tests to assess liver function. In some cases, a biopsy may be necessary to confirm the diagnosis.

Treatment options for bile duct neoplasms depend on several factors, including the location and stage of the tumor, as well as the patient's overall health. Surgical resection is the preferred treatment for early-stage tumors, while chemotherapy and radiation therapy may be used in more advanced cases. For patients who are not candidates for surgery, palliative treatments such as stenting or bypass procedures may be recommended to relieve symptoms and improve quality of life.

Retroperitoneal neoplasms refer to abnormal growths or tumors that develop in the retroperitoneal space. This is the area located behind the peritoneum, which is the membrane that lines the abdominal cavity and covers the abdominal organs. The retroperitoneal space contains several vital structures such as the kidneys, adrenal glands, pancreas, aorta, and lymphatic vessels.

Retroperitoneal neoplasms can be benign or malignant (cancerous). Malignant retroperitoneal neoplasms are often aggressive and can invade surrounding tissues and organs, leading to various complications. Common types of retroperitoneal neoplasms include lymphomas, sarcomas, and metastatic tumors from other primary sites. Symptoms may vary depending on the size and location of the tumor but can include abdominal or back pain, weight loss, and swelling in the legs. Diagnosis typically involves imaging studies such as CT scans or MRI, followed by a biopsy to determine the type and grade of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Salivary gland neoplasms refer to abnormal growths or tumors that develop in the salivary glands. These glands are responsible for producing saliva, which helps in digestion, lubrication of food and maintaining oral health. Salivary gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign neoplasms are slow-growing and typically do not spread to other parts of the body. They may cause symptoms such as swelling, painless lumps, or difficulty swallowing if they grow large enough to put pressure on surrounding tissues.

Malignant neoplasms, on the other hand, can be aggressive and have the potential to invade nearby structures and metastasize (spread) to distant organs. Symptoms of malignant salivary gland neoplasms may include rapid growth, pain, numbness, or paralysis of facial nerves.

Salivary gland neoplasms can occur in any of the major salivary glands (parotid, submandibular, and sublingual glands) or in the minor salivary glands located throughout the mouth and throat. The exact cause of these neoplasms is not fully understood, but risk factors may include exposure to radiation, certain viral infections, and genetic predisposition.

A pancreatectomy is a surgical procedure in which all or part of the pancreas is removed. There are several types of pancreatectomies, including:

* **Total pancreatectomy:** Removal of the entire pancreas, as well as the spleen and nearby lymph nodes. This type of pancreatectomy is usually done for patients with cancer that has spread throughout the pancreas or for those who have had multiple surgeries to remove pancreatic tumors.
* **Distal pancreatectomy:** Removal of the body and tail of the pancreas, as well as nearby lymph nodes. This type of pancreatectomy is often done for patients with tumors in the body or tail of the pancreas.
* **Partial (or segmental) pancreatectomy:** Removal of a portion of the head or body of the pancreas, as well as nearby lymph nodes. This type of pancreatectomy is often done for patients with tumors in the head or body of the pancreas that can be removed without removing the entire organ.
* **Pylorus-preserving pancreaticoduodenectomy (PPPD):** A type of surgery used to treat tumors in the head of the pancreas, as well as other conditions such as chronic pancreatitis. In this procedure, the head of the pancreas, duodenum, gallbladder, and bile duct are removed, but the stomach and lower portion of the esophagus (pylorus) are left in place.

After a pancreatectomy, patients may experience problems with digestion and blood sugar regulation, as the pancreas plays an important role in these functions. Patients may need to take enzyme supplements to help with digestion and may require insulin therapy to manage their blood sugar levels.

Hydroxy acids are a class of chemical compounds that contain both a carboxylic acid group and a hydroxyl group. They are commonly used in dermatology and cosmetic products for their exfoliating, moisturizing, and anti-aging properties. The two main types of hydroxy acids used in skincare are alpha-hydroxy acids (AHAs) and beta-hydroxy acids (BHAs).

Alpha-hydroxy acids include compounds such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid. They work by breaking down the "glue" that holds dead skin cells together, promoting cell turnover and helping to improve the texture and tone of the skin. AHAs are also known for their ability to improve the appearance of fine lines, wrinkles, and age spots.

Beta-hydroxy acids, on the other hand, are primarily represented by salicylic acid. BHAs are oil-soluble, which allows them to penetrate deeper into the pores and exfoliate dead skin cells and excess sebum that can lead to clogged pores and acne breakouts.

It is important to note that hydroxy acids can cause skin irritation and sensitivity to sunlight, so it is recommended to use sunscreen and start with lower concentrations when first incorporating them into a skincare routine.

Pancreaticoduodenectomy, also known as the Whipple procedure, is a complex surgical operation that involves the removal of the head of the pancreas, the duodenum (the first part of the small intestine), the gallbladder, and the distal common bile duct. In some cases, a portion of the stomach may also be removed. The remaining parts of the pancreas, bile duct, and intestines are then reconnected to allow for the digestion of food and drainage of bile.

This procedure is typically performed as a treatment for various conditions affecting the pancreas, such as tumors (including pancreatic cancer), chronic pancreatitis, or traumatic injuries. It is a major surgical operation that requires significant expertise and experience to perform safely and effectively.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

... is a type of tumor in the cystadenocarcinoma grouping. It can occur in the breast as well as in the ... Honma N, Sakamoto G, Ikenaga M, Kuroiwa K, Younes M, Takubo K (August 2003). "Mucinous cystadenocarcinoma of the breast: a case ... "Ovarian mucinous cystadenocarcinoma , Radiology Reference Article". Radiopaedia.org. Retrieved 25 April 2022. v t e (Articles ...
... mucinous bronchioloalveolar carcinoma, signet ring cell adenocarcinoma, mucinous cystadenocarcinoma, and mucinous "colloid" ... may be of use in differentiating primary mucinous cystadenocarcinoma of the lung from metastatic lung tumors due to mucinous ... Mucinous cystadenocarcinoma of the lung (MCACL) is a very rare malignant mucus-producing neoplasm arising from the uncontrolled ... November 2003). "Pulmonary mucinous cystadenocarcinoma: report of a case and review of the literature". The Annals of Thoracic ...
"Primary Breast Mucinous Cystadenocarcinoma and Review of Literature". Cureus. 14 (3): e23098. doi:10.7759/cureus.23098. PMC ...
Cystadenocarcinomas can be classified into serous cystadenocarcinomas and mucinous cystadenocarcinomas.[citation needed] Among ... Papillary serous cystadenocarcinoma Ovarian serous cystadenoma "Ovarian papillary cystadenocarcinoma". Female Genital Pathology ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular epithelium, in which cystic ... A cystadenocarcinoma contains complex multi-loculated cyst but with exuberant solid areas in places. It usually presents with ...
Biliary cystadenoma and cystadenocarcinoma constitute less than 5% of intrahepatic cysts originating from the bile duct. ... ovarian mucinous cystadenoma Pancreas-pancreatic mucinous cystadenoma Peritoneum-peritoneal mucinous cystadenoma Liver-mucinous ... Pancreatic mucinous cystadenoma or mucinous cystadenoma of the pancreas (MCN) are a type of mucinous cystic neoplasm of the ... Mucinous cystadenoma is a benign cystic tumor lined by a mucinous epithelium. It is a type of cystic adenoma (cystadenoma). ...
Endometrioid cystadenoma (8380) Appendix: The term mucinous cystadenoma is an obsolete term for appendiceal mucinous neoplasm ... When malignant, it is called cystadenocarcinoma. When not otherwise specified, the ICD-O coding is 8440/0. However, the ... "Appendix - Other tumors - Mucinous neoplasms (LAMN and HAMN)". Topic Completed: 1 October 2017. Revised: 11 December 2019 ... ISBN 978-1-4160-2999-1. Serous cystadenoma of pancreas at eMedicine Biliary cystadenoma/cystadenocarcinoma at eMedicine v t e ( ...
... cystadenocarcinoma, mucinous MeSH C04.557.470.200.025.480.230 - cystadenocarcinoma, papillary MeSH C04.557.470.200.025.480.240 ... mucinous MeSH C04.557.470.590.480.230 - cystadenocarcinoma, papillary MeSH C04.557.470.590.480.240 - cystadenocarcinoma, serous ... mucinous, and serous MeSH C04.557.470.590.075 - adenocarcinoma, mucinous MeSH C04.557.470.590.340 - carcinoma, mucoepidermoid ... mucinous MeSH C04.557.470.035.320.230 - cystadenoma, papillary MeSH C04.557.470.035.320.240 - cystadenoma, serous MeSH C04.557. ...
Sebaceous carcinoma Sebaceous lymphadenocarcinoma Cystadenocarcinoma Low-grade cribriform cystadenocarcinoma Mucinous ...
... mucinous/serous) Cystadenocarcinoma Islet cell tumors (neuroendocrine tumors) Papillary cystic neoplasms Lymphoma Acinar cell ...
Pancreatic mucinous cystadenoma Pancreatic mucinous cystadenocarcinoma (Articles needing additional references from January ... Pancreatic serous cystadenoma Pancreatic serous cystadenocarcinoma Pancreatic mucinous cystic tumors (13.4%) ... Pancreatic intraductal papillary mucinous tumors (most common diagnosis - 52.6%) Pancreatic serous cystic tumors (20.6%) ... Among this heterogeneous group, benign neoplasms predominate, particularly those with mucinous lining. Age at presentation, ...
Mucinous tumors include mucinous adenocarcinoma and mucinous cystadenocarcinoma. Mucinous adenocarcinomas make up 5-10% of ... Advanced mucinous adenocarcinomas have a poor prognosis, generally worse than serous tumors, and are often resistant to ... Estrogen HRT with or without progestins increases the risk of endometrioid and serous tumors but lowers the risk of mucinous ... Almost 100% of rare mucinous carcinomas have mutations in KRAS and amplifications of ERBB2 (also known as Her2/neu). Overall, ...
As primary ovarian mucinous tumors are usually unilateral (in one ovary), the presentation of bilateral mucinous tumors ... 75% are benign or of borderline malignancy, and 25% are malignant The malignant form of this tumor, serous cystadenocarcinoma, ... of primary mucinous tumors are bilateral. May form very large cystic masses, with recorded weights exceeding 25 kg Mucinous ... Mucinous tumors: Closely resemble their serous counterparts but unlikely to be bilateral Somewhat less common, accounting for ...
... such as the intraductal papillary mucinous neoplasm and the pancreatic mucinous cystadenoma), serous cystic neoplasms are ... "serous cystadenocarcinoma".[citation needed] These lesions rarely require surgery unless they are symptomatic or the diagnosis ... Ovarian serous cystadenoma Pancreatic mucinous cystadenoma Solid pseudopapillary neoplasm Jais B, Rebours V, Malleo G, Salvia R ...
M8470/2 Mucinous cystadenocarcinoma, non-invasive (C25._) M8470/3 Mucinous cystadenocarcinoma/ NOS (C56.9) Pseudomucinous ... NOS M8471/3 papillary mucinous cystadenocarcinoma (C56.9) Papillary pseudomucinous cystadenocarcinoma M8472/1 Mucinous cystic ... Papillary mucinous tumor of low malignant potential M8480/0 Mucinous adenoma M8480/3 Mucinous adenocarcinoma Mucinous carcinoma ... M9015/3 Mucinous adenocarcinofibroma Malignant mucinous adenofibroma Mucinous cystadenocarcinofibroma Malignant mucinous ...
Mucinous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. It can occur in the breast as well as in the ... Honma N, Sakamoto G, Ikenaga M, Kuroiwa K, Younes M, Takubo K (August 2003). "Mucinous cystadenocarcinoma of the breast: a case ... "Ovarian mucinous cystadenocarcinoma , Radiology Reference Article". Radiopaedia.org. Retrieved 25 April 2022. v t e (Articles ...
Tag: mucinous cystadenocarcinoma. Primary retroperitoneal mucinous cystadenocarcinoma in a male patient: a rare case report. ... Posted in Volume 17 (2013) - Issue 3 Tagged cystic neoplasm, laparotomy, male, mucinous cystadenocarcinoma, pathology, ...
MARIANO, Ronaldo Célio et al. Papillary mucinous cystadenocarcinoma: rare malignant tumor in minor salivary gland. RGO, Rev. ... was diagnosed as papillary mucinous papillary mucinous cystadenocarcinoma. Nonetheless, the cellular atypia found was ... Clinical case description of a papillary mucinous cystadenocarcinoma, extremely rare malignant tumor in the salivary gland and ...
Serous cystadenocarcinoma. - Mucinous cystadenoma. - Mucinous borderline tumour. - Mucinous cystadenocarcinoma. - Endometrioid ...
Histology reported a mucinous cystadenocarcinoma of low malignant potential. Image courtesy of C. William Helm, MBBChir. View ... Histology reported a mucinous cystadenocarcinoma of low malignant potential. Image courtesy of C. William Helm, MBBChir. View ... Histology reported a mucinous cystadenocarcinoma of low malignant potential. Courtesy Patrick OKane, MD. View Media Gallery ... Histology reported a mucinous cystadenocarcinoma of low malignant potential. Image courtesy of C. William Helm, MBBChir. ...
mucinous appendiceal cystadenocarcinoma Sat Oct 14, 2006 10:44 am. Majafrytka. 136. Appendix cancer - Appendiceal Moderator ...
mucinous appendiceal cystadenocarcinoma Sat Oct 14, 2006 10:44 am. Majafrytka. 136. Appendix cancer - Appendiceal Moderator ...
serous cystadenocarcinoma * mucinous cystadenocarcinoma - borderline lesion * mucinous cystadenocarcinoma * endometroid ...
A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma. Ann Surg. 1993 ...
Unusual Presentation of Pancreatic Mucinous Cystadenocarcinoma by Spontaneous Splenic Rupture Dig Surg (January,2001) ...
D. Mucinious cystadenocarcinoma Explanation. The presentation of intraperitoneal mucus is indicative of mucinous ... Most common ovarian cancer? serous cystadenocarcinoma. Most common benign tumor in females? leiomyoma. Most common place to ... cystadenocarcinoma. Since the presentation is fairly unique, this makes for a good test question. All of the answers listed are ...
Inguinal Metastases from Mucinous Cystadenocarcinoma of the Pancreas: A Rare Presentation. NHG Annual Scientific Congress 2004 ...
Mucinous cystadenocarcinoma Serous cystadenoma Submeter. DISCUSSION. Cytology examination revealed hyaline material, epithelial ... Machado N, al Qadhi H, al Wahibi K. Intraductal papillary mucinous neoplasm of pancreas. N Am J Med Sci 2015;7:160. ... Tanaka M. Intraductal papillary mucinous neoplasm of the pancreas as the main focus for early detection of pancreatic ...
Mucinous cystadenocarcinoma account for about a fifth of appendix tumours, these produces mucin (a jelly-like substance). ... Appendiceal mucinous neoplasms constitute a diagnostic spectrum ranging from adenoma to mucinous adenocarcinoma. To date, many ... Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits.. Ann Surg Oncol. 2019 ... These groups are adenoma, serrated polyp, low-grade appendiceal mucinous neoplasm, high-grade appendiceal mucinous neoplasm, ...
Mucinous cystadenocarcinoma - A rare, cystic tumor filled with mucin (a thick fluid) that occurs in the tail of the pancreas ... Intraductal papillary-mucinous neoplasm (IPMN) - A cystic tumor that develops in the main pancreatic duct or a side branch ...
Higa E, Rosai J, Pizzimbono CA, Wise L. Mucosal hyperplasia, mucinous cystadenoma, and mucinous cystadenocarcinoma of the ... Mucinous cystadenoma of the appendix associated with adenocarcinoma of the sigmoid colon and hepatocellular carcinoma of the ... According to International Classification of Diseases for Oncology appendiceal tumors are divided in to five classes: Mucinous ... Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with ...
... mucinous cystadenocarcinoma (15 cases, 11.63%), and poorly differentiated adenocarcinoma (24 cases, 18.61%). Healthy control ... Histopathological types included serous cystadenocarcinoma (49 cases, 37.98%), endometrioid carcinoma (41 cases, 31.78%), ...
With a presumptive diagnosis of mucinous cystadenoma / cystadenocarcinoma, the patient underwent abdominal exploration for a ...
intraductal papillary mucinous neoplasm (IPMN). *mucinous cystadenocarcinoma. *pancreatoblastoma. *serous cystadenocarcinoma. * ...
... and mucinous cystadenocarcinoma, adenomyoepithelioma, and secretory carcinoma. In addition, benign lesions such as usual ductal ...
Cystadenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Vulvar Neoplasms, Sex Cord-Gonadal Stromal Tumors, Adrenocortical ... Cystadenocarcinoma, Paraganglioma, Chordoma, Hemangiosarcoma, Fibromatosis, Aggressive, Adenocarcinoma, Mucinous, Nerve Sheath ...
Histologically, 46,6% of the tumors (82 cases) were serous cystadenocarcinoma, 34,1% (60 cases) were mucinous ... The pathological specimens that could not be discerned if they are serous or mucinous were accepted as undifferentiated. The ... The histologic types are as follows: (1) high grade clear cell; (2) high grade endometrioid; (3) high grade mucinous; (4) high ... cystadenocarcinoma, 9,7% (17 cases) were endometrioid carcinoma, and 5,1% (9 cases) were clear cell carcinoma. 8 of the cases ...
... but also that he had mucinous cystadenocarcinoma.. "Dr. Shah told me that she had stopped in the middle of the operation and ...
... mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. ... or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed ... Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/ ...
... mucinous cystadenocarcinoma, signet ring adenocarcinoma and clear cell adenocarcinoma. Since this classification work, thyroid ... AAH is considered a precursor for non mucinous BAC; there is no defined pre-invasive lesion for mucinous BAC. ... Where BAC of Clara type II cells (nonmucinous) are usually solitary nodules and have very good prognosis, mucinous-type ...
Cystadenocarcinoma. Neoplasms, Cystic, Mucinous, and Serous. Pembrolizumab. Antineoplastic Agents, Immunological. ... Cystadenocarcinoma, Serous. Carcinoma, Squamous Cell. Carcinoma. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic ...
... mucinous cystadenocarcinoma [4]). ...
mucinous adenocarcinoma cell line:JHOM-1.CNhs11752.10648-109A9. 0.00. mucinous cystadenocarcinoma cell line:MCAS. ... serous cystadenocarcinoma cell line:HTOA.CNhs11827.10693-109F9. 0.00. signet ring carcinoma cell line:Kato III.CNhs10753.10436- ...
mucinous adenocarcinoma cell line:JHOM-1.CNhs11752.10648-109A9. 0.00. mucinous cystadenocarcinoma cell line:MCAS. ... serous cystadenocarcinoma cell line:HTOA.CNhs11827.10693-109F9. 0.00. signet ring carcinoma cell line:Kato III.CNhs10753.10436- ...
  • With a presumptive diagnosis of mucinous cystadenoma / cystadenocarcinoma, the patient underwent abdominal exploration for a possible Whipple procedure (pancreaticoduodenectomy). (vesalius.com)
  • To study the relationship between carcinoembryonic antigen (CEA) level, intraductal papillary mucinous neoplasm (IPMN) subtype, and the presence of invasive carcinoma. (gastrores.org)
  • Intraductal papillary mucinous neoplasm (IPMN) is a substantial subclass of pancreatic pathology, representing 20-50% of cystic pancreatic neoplasms [ 1 - 3 ]. (gastrores.org)
  • In addition, a variety of other rare breast lesions reveals a papillary architecture such as tall cell carcinoma with reversed polarity (TCCRP) and mucinous cystadenocarcinoma, adenomyoepithelioma, and secretory carcinoma. (nih.gov)
  • Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. (sncrf.org)
  • The purpose of this case-control study was to compare the prognoses of women with stage III mucinous ovarian carcinoma (MOC) who received maximal or optimal cytoreduction followed by paclitaxel plus carboplatin chemotherapy to those of women with stage III serous epithelial ovarian cancer (EOC) treated in the similar manner. (biomedcentral.com)
  • Mucinous Carcinoma, Upper Gastro-Intestinal Tract. (booksdo.com)
  • Mucinous breast carcinoma with tall columnar cells. (nih.gov)
  • Mucinous metaplasia of breast carcinoma with macrocystic transformation resembling ovarian mucinous cystadenocarcinoma in a case of synchronous bilateral infiltrating ductal carcinoma. (nih.gov)
  • However, there was no correlation between CEA level and cystic mucinous secretions or mucinous epithelial cytoplasm CEA staining, mucin glycoprotein expression, size of lesion, grade of dysplasia or presence of invasive carcinoma. (gastrores.org)
  • In addition to CEA being used to stratify mucinous vs. non-mucinous lesions, several studies have attempted to correlate pancreatic cyst fluid CEA level and the presence of invasive carcinoma, with discordant results [ 17 , 18 ]. (gastrores.org)
  • Researchers isolated mucinous cystadenocarcinoma and high-grade papillary serous carcinoma cell lines. (insiderup.com)
  • Clinical case description of a papillary mucinous cystadenocarcinoma, extremely rare malignant tumor in the salivary gland and difficult to diagnose, in geriatric patient. (bvsalud.org)
  • Despite the favorable clinical features, after surgical removal, was diagnosed as papillary mucinous papillary mucinous cystadenocarcinoma. (bvsalud.org)
  • During the diagnostic workup for pancreatic cysts, CEA is often utilized to distinguish those pancreatic cystic lesions that are likely to be mucinous [ 13 - 16 ]. (gastrores.org)
  • Malignant tumors of the appendix can be classified into mucinous epithelial neoplasms, neuroendocrine tumors (typical carcinoids), goblet cells or composite carcinoids, lymphomas, adenocarcinomas and lymphoid or mesenchymal sarcomas. (rojes.org)
  • Mucinous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. (wikipedia.org)
  • We wondered whether the worse prognosis associated with mucinous histology is also valid when age, tumor grade, substage of disease, and extent of RD are matched with serous histology in women with stage III EOC who have undergone primary CRS followed by standard intravenous paclitaxel plus carboplatin chemotherapy. (biomedcentral.com)
  • Mucinous cystadenocarcinoma account for about a fifth of appendix tumours, these produces mucin (a jelly-like substance). (cancerindex.org)
  • When Laureanno woke up from the procedure, however, he learned that he not only still had his appendix, but also that he had mucinous cystadenocarcinoma. (tuftsmedicalcenter.org)
  • Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. (sncrf.org)
  • Mucinous Cystadenocarcinoma, Appendix. (booksdo.com)
  • Mucinous cystadenocarcinoma of the appendix complicated with spontaneous cutaneous fistula. (rojes.org)
  • Appendiceal mucinous neoplasms represent an extremely small percentage of all appendectomy specimens. (rojes.org)
  • Appendicular mucinous neoplasms are a rare disease for which diagnostic and therapeutic management is a challenge. (rojes.org)
  • 2] Aleter A, El Ansari W, Toffaha A, Ammar A, Shahid F, Abdelaal A. Epidemiology, histopathology, clinical outcomes and survival of 50 cases of appendiceal mucinous neoplasms: Retrospective cross-sectional single academic tertiary care hospital experience. (rojes.org)
  • Inguinal Metastases from Mucinous Cystadenocarcinoma of the Pancreas: A Rare Presentation. (sgh.com.sg)
  • women with mixed histologies including mucinous tumors combined with endometrioid, serous, clear-cell, and/or other histologic types were excluded. (biomedcentral.com)
  • Histologically, more than half of appendicular tumors are of neuroendocrine origin, while the rest are adenocarcinomas (mucinous, signet ring or non-mucin-secreting). (rojes.org)
  • Histology reported a mucinous cystadenocarcinoma of low malignant potential. (medscape.com)
  • The histopathological examination of the appendectomy specimen established the diagnosis of infiltrative mucinous adenocarcinoma at the level of the adventitia. (rojes.org)
  • The mucinous variant of columnar cell lesions. (nih.gov)
  • Primary mammary mucinous cystadenocarcinoma: cytological and histological findings. (nih.gov)
  • Pseudomyxoma Peritonei ( PMP ) is a more common name given to the "jelly belly" syndrome caused by mucinous adenoma and mucinous adenocarcinoma. (cancerindex.org)
  • Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. (nih.gov)
  • For a long time they were misdiagnosed as mucinous cystadenocarcinoma, ductal adenocarcinoma in situ, or chronic pancreatitis. (web.app)
  • Primary appendiceal adenocarcinoma is a rare tumor, mucinous variety being common. (biomedcentral.com)
  • Later on, after appendectomy, histopathology of appendicular stump was suggestive of mucinous adenocarcinoma. (biomedcentral.com)
  • HP slide showing mucinous adenocarcinoma. (biomedcentral.com)
  • Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. (ucbraid.org)
  • This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. (ucbraid.org)
  • More than 90% of CCs are adenocarcinomas, with different histological variants including adenocarcinoma, papillary adenocarcinoma, intestinal-type adenocarcinoma, and mucinous adenocarcinoma [ 1 , 2 , 6 ]. (gastrores.org)
  • There are five subtypes of ovarian carcinoma that are sufficiently distinct and well-characterized that they should be considered to be different diseases, i.e. high-grade serous, clear cell, endometrioid, mucinous and low-grade serous, from most to least common, respectively. (nih.gov)
  • 2. Mucinous metaplasia of breast carcinoma with macrocystic transformation resembling ovarian mucinous cystadenocarcinoma in a case of synchronous bilateral infiltrating ductal carcinoma. (nih.gov)
  • 4. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma. (nih.gov)
  • 5. Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: review of patients over an 8-year period. (nih.gov)
  • 12. Metastasis of breast carcinoma to a primary mucinous cystadenocarcinoma of the ovary. (nih.gov)
  • 13. Pure and mixed mucinous carcinoma of the breast: fine needle aspiration cytology findings and review of the literature. (nih.gov)
  • 16. Mammary synchronous mucinous cystadenocarcinoma and columnar cell mucinous carcinoma: a case report. (nih.gov)
  • 19. A case of mucinous carcinoma of the breast in which needle tract seeding was diagnosed by preoperative diagnostic imaging. (nih.gov)
  • Consequently, TAG-72 was useful for the detection of ovarian carcinoma, especially for monitoring mucinous cystadenocarcinoma, and it is localized in the microvilli and apical cytoplasmic membrane of cystadenocarcinoma cells. (nih.gov)
  • Intraductal papillary mucinous neoplasm of the pancreas (IPMN) was first described in 1982 when four patients with pancreatic carcinoma and favorable outcomes were reported. (web.app)
  • Mucinous Cystadeno Carcinoma is rare which malignant, cystic tumor is and it is similar to IPMN this occurs at one area (at tail of pancreas), cyst is filled with mucin and these tumors are mostly seen in women [ 45 - 48 ]. (rroij.com)
  • Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. (ucbraid.org)
  • This monoclonal antibody is used for the identification of primary and metastatic non-mucinous ovarian carcinoma and ovarian carcinoma cells in peritoneal fluids. (abforresearch.nl)
  • Although CA125 expressed a remarkable diagnostic efficiency with serous cystadenocarcinoma, it was less efficient with mucinous cystadenocarcinoma. (nih.gov)
  • Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. (musc.edu)
  • A BALB/c mouse was immunized with cyst fluid of a human serous cystadenocarcinoma of the ovary. (abforresearch.nl)
  • Mucinous cystic neoplasm is a unique subset within the hepatic cyst differential and includes the subgroup of mucinous cystic neoplasm, also referred to as biliary cystadenomas (BCA) and cystadenocarcinomas (BCAC). (nih.gov)
  • Metastatic Mucinous Cystadenocarcinoma ovary: An unusual presentation. (stmatthews.edu)
  • 15. The level of carcinoembryonic antigen and the presence of mucin as predictors of cystic pancreatic mucinous neoplasia. (nih.gov)
  • 1. Primary mammary mucinous cystadenocarcinoma: cytological and histological findings. (nih.gov)
  • Also, histological localization of TAG-72 in the microvilli and apical cytoplasmic membrane was demonstrated by electron microscopy using MAb B72.3 and samples of seromucinous cystadenocarcinoma (mixed type). (nih.gov)
  • Immunohistochemical staining with MAbs B72.3 and CC49 in the cytoplasm was stronger than that in the cell membrane in tissues from mucinous cystadenocarcinomas. (nih.gov)
  • Microscopic observation showed that the cystic walls were lined mainly by single-layered tall mucinous columnar epithelium (Fig. 2 a). (biomedcentral.com)
  • The antibody stains 80% of non-mucinous primary and metastatic ovarian cancers. (abforresearch.nl)
  • A mucinous origin of the YDOV-151 was evident from light microscopy, and its epithelial-like character was confirmed with electron microscopy. (elsevierpure.com)
  • Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (musc.edu)
  • Despite the favorable clinical features, after surgical removal, was diagnosed as papillary mucinous papillary mucinous cystadenocarcinoma. (bvsalud.org)
  • We have therefore established a new human ovarian cancer cell line, YDOV-151, derived from the mucinous cystadenocarcinoma and characterized it by the microarray analyses. (elsevierpure.com)
  • The newly established ovarian cancer cell line, YDOV-151, would be a useful model for elucidating the biology and the pathogenesis of mucinous cystadenocarcinoma. (elsevierpure.com)
  • This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications. (musc.edu)
  • Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles. (musc.edu)
  • To our knowledge, there are no reports of mucinous ovarian tumors accompanied by LGESS with myxoid change. (biomedcentral.com)